A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy - PubMed

A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy - PubMed

A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy

Yinglian Pan 1, Li Ping Jia 2, Yuzhu Liu 2, Yiyu Han 2, Qian Li 3, Qin Zou 3, Zhongpei Zhang 3, Jin Huang 4, Qingchun Deng 5

Affiliations 

• PMID: 32950050
 
• DOI: 10.1186/s13048-020-00712-w

Free article

Abstract

Background: In this study we aimed to identify a prognostic signature in BRCA1/2 mutations to predict disease progression and the efficiency of chemotherapy ovarian cancer (OV), the second most common cause of death from gynecologic cancer in women worldwide.

Methods: Univariate Cox proportional-hazards and multivariate Cox regression analyses were used to identifying prognostic factors from data obtained from The Cancer Genome Atlas (TCGA) database. The area under the curve of the receiver operating characteristic curve was assessed, and the sensitivity and specificity of the prediction model were determined.

Results: A signature consisting of two long noncoding RNAs(lncRNAs), Z98885.2 and AC011601.1, was selected as the basis for classifying patients into high and low-risk groups (median survival: 7.2 years vs. 2.3 years). The three-year overall survival (OS) rates for the high- and low-risk group were approximately 38 and 100%, respectively. Chemotherapy treatment survival rates indicated that the high-risk group had significantly lower OS rates with adjuvant chemotherapy than the low-risk group. The one-, three-, and five-year OS were 100, 40, and 15% respectively in the high-risk group. The survival rate of the high-risk group declined rapidly after 2 years of OV chemotherapy treatment. Multivariate Cox regression associated with other traditional clinical factors showed that the 2-lncRNA model could be used as an independent OV prognostic factor. Analyses of data from the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) indicated that these signatures are pivotal to cancer development.

Conclusion: In conclusion, Z98885.2 and AC011601.1 comprise a novel prognostic signature for OV patients with BRCA1/2 mutations, and can be used to predict prognosis and the efficiency of chemotherapy.

Keywords: BRCA1/2 gene; Chemotherapy; Efficiency; Long non-coding RNA; Mutations; Ovarian cancer; Prognostic biomarker.

Similar articles

• Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.

  Zhao QJ, Zhang J, Xu L, Liu FF.World J Gastroenterol. 2018 Aug 14;24(30):3426-3439. doi: 10.3748/wjg.v24.i30.3426.PMID: 30122881 Free PMC article.
• Identification of a RNA-Seq Based 8-Long Non-Coding RNA Signature Predicting Survival in Esophageal Cancer.

  Fan Q, Liu B.Med Sci Monit. 2016 Dec 28;22:5163-5172. doi: 10.12659/msm.902615.PMID: 28028307 Free PMC article.
• LncRNAs KB-1836B5, LINC00566 and FAM27L are associated with the survival time of patients with ovarian cancer.

  Li H, Gong M, Zhao M, Wang X, Cheng W, Xia Y.Oncol Lett. 2018 Sep;16(3):3735-3745. doi: 10.3892/ol.2018.9143. Epub 2018 Jul 12.PMID: 30127984 Free PMC article.
• Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma.

  Zheng S, Zheng D, Dong C, Jiang J, Xie J, Sun Y, Chen H.J Cancer Res Clin Oncol. 2017 Sep;143(9):1649-1657. doi: 10.1007/s00432-017-2411-9. Epub 2017 Apr 13.PMID: 28409273
• Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.

  Xu L, Wu Y, Che X, Zhao J, Wang F, Wang P, Qu X, Liu Y, Li Z.DNA Cell Biol. 2019 Dec;38(12):1519-1528. doi: 10.1089/dna.2019.4826. Epub 2019 Oct 29.PMID: 31657627